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SUMMARY 
Liver transplantation has been developed to the point of a service operation, the exploitation of 
which depends upon the establishment of multiple regional centers. The increased use of this procedure 
will permit the delivery of optimum health care to victims of end stage liver disease. 
Supported by research grants from the Veterans Ad· 
ministration; by project grant AM·29961 from the 
National Institutes of Health and by grant RR·000084 
from the General Clinical Research Centers Program 
of the Division of Research Resources, National Ins-
titutes of Health. 
To be a service, a new surgical procedure must 
be within the capability of more than the occasional 
surgeon. In addition the indications for its use should 
be clear, and the results should be good enough to 
justify the effort and expense. In this communicati· 
on we will indicate that orthotopic liver transplanta-
tion has met all three of these criteria. 
METHODS 
Two hundred and ninety-six patients were trea-
ted from March 1963 through April 1983. Until the 
end of 1979, "conventional" immunosuppression was 
used with azathioprine and prednisone to which ALG 
was added in almost all cases (1,2). In 16 patients trea-
ted in 1971 and 1972 cyclophosphamide was sub-
stituted for azathioprine. From early 1980 onward, 
immunosuppresion was with cyclosporine and stero-
ids. The surgical and medical techniques have been 
described elsewhere (1,2). 
The results were analyzed before and after the 
introduction of cyclosporine-steroid therapy. In the 
post-1980 era the ilT'pact was assessed of a greatly 
expanded volume of cases, the use of veno-venous 
bypasses with and without heparin, and the systema· 
tic training of younger surgeons whose objective co· 
uld be to set up new centers. In all of the case materi-
al, the influence of original disease upon the results 
also was examined. 
RESULTS 
Survival With Conventional 
Immunosuppression (1963 - 1979) 
From 1963 to the end of 1979, 170 consecutive 
patients were treated, an average case load of less 
than a dozen per year. Fifty·six (32.9%) of the reci-
pients lived for at least one year, and 32 (18.8%) are 
still alive with followups of 3 1/2 to 13 1/2 years. 
. Six of the residual group are more than 10 years post· 
operative, and 26 are more than 5 years. Only one 
patient who lived for as long as 5 years has subsequ-
ently died. 
The patient survival during the first 18 months is 
summarized in Table 1. The predominant mortality 
was in the first three postoperative months and was 
due mainly to technical surgical accidents,acceptance 
of recipients with hopelessly advanced disease, the 
use of damaged liver grafts, the inability to control 
rejection, and a variety of infections (1,2). Most of 
the deaths in the first half of the second year (Table 
1) were due to chronic rejection (2)_ 
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TABLE 1 ACTUAL EIGHTEEN MONTH SURVIVAL OF 210 
CONSECUTIVE RECIPIENTS 
TREATMENT NO. 
1 
Triple Drug Conventional 170 120 
(1963 - 1979) 
(58%) 
Cyclosporine . Steroids 40 32 
(1980 -1981) (80%) 
Survival With Cyciosporine·Steroid Therapy 
(1980 - 1981) 
Fourtee'1 patients were treated in 1980 and 26 in 
1982; follow ups of 18 to 38 months are available for 
those still living. The one year survival was 28/40 
(70%) (Table 1). Three of the one year survivors died 
in the 13th, 16th, and 20th months of recurrent cho-
langiocarcinoma, recurrent Budd·Chiari syndrome, 
and chronic rejection (with an unsuccessful attempt 
at retransplantion) respectively. The actual 18 month 
survival (Table 1) was 65% and the actuarial 2 year 
survival is projected at 60%. 
The Breakout Year of .1982 
Until 1982, virtually all of the liver transplanta· 
tions in our series over a span of almost 19 years were 
performed by a single surgeon (Table 2). The same 
surgeon also had carried out all of the donor operati-
ons in the earliest years of these efforts and in all ca-
ses since 1979. The image created was of a procedure 
that was too difficult to be taught easily to other 
teams. Thus, policy changes were instituted upon 
which it was thought that the practicality of liver 
transplantation would hinge. 
The donor operations ... Beginning on 1 January 
1982, organ harvest teams which had been trained 
throughout the preceding year assumed responsibility 
for 100% of the procurement procedures (Table 2). 
Anyone of 5 faculty members (2 were urologists and 
3 were general surgeons) headed the teams. In additi-
on, training of other teams was begun in distant cities 
with the eventual objective of promoting graft hepa-
tectomies by local surgeons instead of by mobile Pitt-
sburgh teams. 
TIME IN MONTHS 
2 6 12 18 
95 65 56 47 
(55.9%) (33.2%) (32.9%) (27_6%) 
31 29 28 26 
(77.5%) (72.5%) (70%) (65%) 
Recipient operations ... The diffusion of recipient 
operative responsibility from one to several surgeons 
also began in 1982 during which 40% of the patients 
were treated by young faculty members or fellows 
(Table 2). 
High case volume ... The foregoing changes led to 
a considerable expansion of the clinical efforts. In 
addition to the 62 primary transplantations, 18 re-
ransplantations were carried out bringing the total 
number of liver replacements in 1982 to 80 (Table 2). 
A trial of veno-venous bypasses ... Bypasses were 
used 2 decades ago in the original trials of liver trans-
plantation for decompression of the portal vein and 
inferior vena cava which must be obstructed during 
the hepatectomy and actual transplantation (1). The 
practice was abandoned for many years but tried again 
in 12 cases during the summer of 1982 using pump 
driven bypasses under systemic heparinization. Can-
nulas were placed into the vena cava (via the femoral 
vein) and into the portal vein. The physiologic condi-
tion of the recipients during the anhepatic phase and 
the ease of vascular suturing of the grafts were enor-
mously improved, but it was difficult or impossible 
to reverse the heparin effect which was responsible 
for 3 deaths in the operating room. Of 12 recipients 
who had 14 such bypasses (two were at retransplanta-
tion), only 3 became long term survivors. 
Subsequently pump driven veno-venous bypasses 
without heparin were perfected in the laboratory and 
in 1983 bypasses have been used for most of the 
Jdult patients. This technique has been satisfactory in 
14 recent transplantations and should place the opera-
tion of liver replacement within the grasp of a much 
greater number of surgeons. 
The results in 1982 ... Half of the recipients trea-
ted during this time of major change are alive with 
TABLE 2 THE SHARING OF mof~lAov OPERATIVE 
RESPONSIBILITY BY MULTIPLE SURGEONS 
1963-1979 1980-1981 1982 1983 (4 months) 
New Patients 170 40 62 24 
Total Transplantations 191 45 80 34 
Transplantations by Single 
Surgeon (TES) 187 45 48 10 
(97.9%) (100%) (60%) (29.4%) 
Donor Operations by 
* Single Surgeon (TES) Minority 100% 0% 0% 
*The majority of these donor operations at the University of Colorado were by Dr. Charles Halgrimson. 
follows of 5 to 16 months. The survival of the 1982 
pediatric recipients ( < 18 years) in 16/28 (57.1) a 
figure higher than the 15/34 (44.1 %) achieved during 
1982 in the adults. 
The Pace in 1983 
During the first four months, 24 primary and 10 
retransplantation procedures were carried out, a rate 
which if sustained will total 100 for the year. ;The 
new conditions developed in 1982 have continued 
with more than 70% of the transplantations now per-
formed by young faculty members and fellows '(Tab-
Ie 2) and with almost all adults havin~ veno-~enous 
bypasses. The present survival of new patients is 
17/24 (70.8%), including 8/10 children and 9/14 
adults. 
The Influence of Disease Upon Results 
None of the diseases for which transplantation 
has been performed can be categorically excluded 
from future trials in spite of a very high incidence of 
recurrence of the original disease which has been do-
cumented with primary hepatic malignancies (1,2) 
and with chronic active hepatitis i!" B-virus carriers 
(2). Recurrence of Budd-Chiari syndrome (2,3) and 
primary biliary cirrhosis (3) have been less common· 
Iy seen. 
The one year and current patient survival befo-
re and after the introduction of cyclosporine-steroid 
therapy is summarized in Table 3 for each of the ma-
in disease categories; 237 consecutive patients were 
included whose transplantations were at least one ye-
ar ago with the assumption that this followup period 
would permit detection of aggressively. evolving reo 
currences. The only obvious conclusion is that the 
results have improved after the introduction of cyc-
losporine·steroid therapy no matter what the original 
diagnosis. It is noteworthy that no patients with al-
coholic cirrhosis have been included i~ the cyclospo· 
rine series, a selection bias that will not be acceptable 
in the future. Alcoholic recipients from our earlier 
experience have been followed for as long as a decade. 
The Influence of Disease Stage Upon Results 
The stage of the original disease was of greater 
prognostic importance than its nature. The stage fac· 
. tor was examined in 114 consecutive patients treated 
. in the cyclosporine-steroid era from 3 to 38 months 
ago. Patients who were not continuously hospitalized 
prior to operation were called Class I. Those who 
were hospitalized most of the time but not in Intensive 
Care Unit to the operating room were termed Class 
III. These last patients usually were mentally obtun-
ded or unconscious. Many had the hepatorenal syn-
drome and most were ventilator dependent. The ma-
jority had active gastrointestinal bleeding. 
The perioperative mortality was almost 60% in the 
Class III patients (Table 4). In contrast, the morta· 
lity in the first 6 weeks was only 16% in Class II pati-
ents. The somewhat higher mortality (32%) in Class 
I patients was partly explained by the fact that many 
of theSe recipients had undergone the kinds of opera-
tions in or around the hepatic hilum (such as portaca-
val shunt or biliary tract reconstruction) that greatly 
increase the technical risk (2). Such patients could be 
accepted for candidacy only if they were in the kind 
of reasonable metabolic state that tended to place 
them in the Class I categorY. 
TABLE 3 INFLUENCE OF DISEASE UPON ONE YEAR AND SUBSEOUENT 
SURVIVAL IN 237 PATIENTS· 
CONVENTIONAL THERAPY CYCLOSPORINE-STEROIDS 
NO. 
Biliary Atresia 51 
Non Alcoholic Cirrhosis 46 
Primary Liver Ma lignancy 18 
Alpha-1-Antitrypsin 
Deficiency 11 
**** Other Inborn Errors 4 
Alcoholic Cirrhosis 15 
Primary Biliary 
Cirrhosis 
Sclerosing Cholangitis 
Secondary Biliary 
Cirrhosis 
Budd-Chiari Syndrome 
***** Miscellaneous 
6 
7 
4 
1 
7 
I YEAR 
14 (27%) 
16 (34.8%) 
5 (27.8%) 
6 (54.5%) 
2 (50%) 
4 EOSKT~F 
1 (16.7%) 
2 (28.6%) 
3 (75%) 
1 (1 OOOA;) 
2 (28.6%) 
NOW" 
7 (14%) 
10 (21.7%) 
(5.6%) 
5 (45.5%) 
(25%) 
3 (20%) 
1 (16.7%) 
o (0%) 
2 (50%) 
1 (100%) 
(14.3%) 
NO 
11 
16 
9 
6 
4 
o 
6 
3 
5 
3 
4 
6 
9 
6 
I YEAR NOW··· 
(54.5%) 6 
(56.3%) 8 
(66.7%) 4 
(54.5%) 
(50%) 
(44.4%) 
3 (50%) 3 (50%) 
4 (100%) 4 (100%) 
5 
2 
1 
3 
3 
(83.3%) 5 
(66.7%) 1 
(20%) 1 
(100%) 1 
(75%) 3 
(83.3%) 
{33.3%} 
(20%) 
(33.3%) 
(75%) 
* The same case material was analyzed in detail elsewhere (2) but with shorter foflowups. 
** Followups 3 1/2 to 13 1/2 years. 
** * Followups 1 to 3 1/4 years. 
**** Wilson's Disease (3 examples), Tyrosinemia (2 examples), Glycogen Storage Disease (2 examples), 
Sea Blue Histiocyte Syndrome {1 example}. 
***** Neonatal Hepatitis (3 examples), Congenital Hepatic Fibrosis (2 examples), Byler's Disease (2 exam-
ples), Adenomatosis, Hemachromatosis, Protoporphyria, Acute Hepatitis B (1 example each). 
DISCUSSION 
With the better immunosuppression that became 
available almost 3 1/2 years ago came a revitalization 
of interest in hepatic transplantation. In spite of its 
use in most cases for pathologic conditions which will 
someday be viewed as unrealistically advanced, the 
number of successful liver replacements has sharply 
increased. 
Continuing observation of the first patients trea-
ted with cyclosporinesteroid therapy has dispelled 
scepticism about the ability to use cyclosporine chro-
nically. Forty·two patients have now been followed 
for at least one year after liver transplantation under 
cyclosporine·steroid therapy. Six deaths have occur-
red after one year and all but two have been caused 
by recurrence of the original disease (2 examples of 
30 
metastases from primary hepatic malignancies, 1 each 
of recurrent Budd·Chiari syndrome and chronic B-vi-
rus hepatitis). One patient died of probable airway 
obstruction secondary to acute tonsillitis. Only one 
patient lost a graft to chronic rejection. The degree 
of rehabilitation of long term survivors has been es-
sentially complete. 
The mystique surrounding liver transplantation 
largely has been dispelled by the events of the last 2 
years at our institution and elsewhere. Other units in 
the United States and in other countries have been 
able to mount effective programs. In Pittsburgh,more 
than two thirds of the liver transplantation operations 
are now being done by young faculty members and 
by surgeons in training. The ease which with the ad-
mittedly difficult operation can be performed is be-
ing reduced with the pump driven non-heparin bypas-
ses that are being used this year for the first time. 
TABLE 4 EFFECT OF DISEASE STAGE ON 6-WEEK SURVIVAL 
(114 CONSECUTIVE PATIENTS) 
CLASS 
II 
III 
DEFINITION 
Outpatient Care Dependent 
Hospital Care Dependent 
Intensive Care Unit Dependent 
NO 
63 
25 
26 
SURVIVAL 
68% 
84% 
42% 
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